The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Advances in Hodgkin lymphoma: novel treatments and innovative methods to measure efficacy
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the evolving landscape of Hodgkin lymphoma management, focusing on minimizing toxicities while maintaining excellent results with novel therapies and chemotherapy combinations. Prof. Ansell expresses excitement about ongoing studies investigating new agents in limited-stage patients and the development of innovative methods to measure treatment efficacy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think Hodgkin lymphoma really is undergoing a dramatic change and I think how we’re managing patients is mostly focused now on taking the excellent results we’ve been getting with novel therapies in combination with chemotherapy and really looking to minimize and decrease toxicities. So I think the things I’ve been excited about is initial concerns that some of those great results would not be maintained, have actually kind of not proven true, and the results are holding up extremely well...
I think Hodgkin lymphoma really is undergoing a dramatic change and I think how we’re managing patients is mostly focused now on taking the excellent results we’ve been getting with novel therapies in combination with chemotherapy and really looking to minimize and decrease toxicities. So I think the things I’ve been excited about is initial concerns that some of those great results would not be maintained, have actually kind of not proven true, and the results are holding up extremely well. That’s predominantly been in the advanced stage patients, but now we’re looking to see early stage, limited stage patients – could the same data hold true? So there are a variety of studies looking at improving outcomes in limited stage patients utilizing some of these new agents, so I’m pretty excited about that. I would say the second thing that I’m excited about is just new ways in which we can measure efficacy of therapy, so we’re learning a lot more about ctDNA and other ways to augment our data that we’ve been using for PET, because most of these new therapies we have not used them in a PET-directed or a ctDNA-directed way, and I think that’s the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
